Electrophysiology and ultrastructural changes in mouse sciatic nerve associated with colistin sulfate exposure

Toxicology Mechanisms and Methods

Volumn 22, Issue 8, 2012, Pages 592-596

  Dai, Chongshan ^a   Li, Jichang ^a   Lin, Wei ^a   Li, Guangxing ^a   Sun, Meicheng ^a   Wang, Fengxia ^a   Li, Jian ^b  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Colistin sulfate; Electrophysiology; Neurotoxicity; Sciatic nerve; Ultrastructural pathology

Indexed keywords

COLISTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEMYELINATION; FEMALE; MOUSE; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; TIBIAL NERVE;

ACTION POTENTIALS; ANIMALS; ANTI-BACTERIAL AGENTS; AXONS; BEHAVIOR, ANIMAL; COLISTIN; DEMYELINATING DISEASES; ELECTROPHYSIOLOGY; FEMALE; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED STRAINS; NERVE DEGENERATION; NEURAL CONDUCTION; SCIATIC NERVE; TIME FACTORS; TOXICITY TESTS;

MUS;

EID: 84866549268     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2012.704956     Document Type: Article

References (21)

1. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. 1991. Toxicity of colistin in cystic fbrosis patients. DICP 25:1168-1170.
2. Chow KM, Szeto CC, Hui AC, Li PK. 2004. Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrob Agents 23:213-217.
3. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10:R27.
4. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, Gallego-Lara SL, Madrazo-Osuna J. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111-1118.
5. Hermsen ED, Sullivan CJ, Rotschafer JC. 2003. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17:545-562.
6. Hort-Legrand C, Noah L, Mériguet E, Mésangeau D. 2006. Motor and sensory nerve conduction velocities in Yucatan minipigs. Lab Anim 40:53-57.
7. Huang J, Tang YQ, Sun JY. 2010. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Scand J Infect Dis 42:260-265.
8. Jin L, Li J, Nation RL, Nicolazzo JA. 2009. Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob Agents Chemother 53:4247-4251.
9. Jin L, Li J, Nation RL, Nicolazzo JA. 2011. Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob Agents Chemother 55:502-507.
10. Landman WJ, Dwars RM, Keukens HJ, Berendsen BJ. 2000. Polymyxin E-1 (colistin sulphate) (neuro-)intoxication in young ostriches (Struthio camelus spp.). Avian Pathol 29:593-601.
11. Lehning EJ, Jortner BS, Fox JH, Arezzo JC, Kitano T, LoPachin RM. 2000. gamma-diketone peripheral neuropathy. I. Quality morphometric analyses of axonal atrophy and swelling. Toxicol Appl Pharmacol 165:127-140.
12. rd, Forrest A, Bulitta JB, Tsuji BT. 2010. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 30:1279-1291.
13. Lin B, Zhang C, Xiao X. 2005. Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ter 28:349-354.
14. Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I, Dimopoulou E, Baltopoulos G. 2009. Penetration of colistin into cerebrospinal fuid. Antimicrob Agents Chemother 53:4907-4910.
15. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. 2002. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 11:499-505.
16. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. 2011b. Renal and neurological side efects of colistin in critically ill patients. Ann Intensive Care 1:14.
17. Spapen HD, Honore PM, Gregoire N, Gobin P, de Regt J, Martens GA, Pierard D, Couet W. 2011a. Convulsions and apnoea in a patient infected with New Delhi metallo-ß-lactamase-1 Escherichia coli treated with colistin. J Infect 63:468-470.
18. Wahby K, Chopra T, Chandrasekar P. 2010. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 50:e38-e40.
19. Wallace SJ, Li J, Nation RL, Rayner CR, Taylor D, Middleton D, Milne RW, Coulthard K, Turnidge JD. 2008. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 52:1159-1161.
20. Wang QS, Xie KQ, Zhang CL, Zhu YJ, Zhang LP, Guo X, Yu SF. 2005. Allyl chloride-induced time dependent changes of lipid peroxidation in rat nerve tissue. Neurochem Res 30:1387-1395.
21. Zhang LP, Guo X, Wang QS, Zhu YJ, Xie KQ. Time-dependent changes in compound action potential in hen sciatic nerve treated with tri-ortho-cresyl phosphate. Chin J Pharmacol Toxicol. 2005; 19:387-392.